The use of granulocyte colony stimulating-factor (G-CSF) is safe in patients with limited-stage small-cell lung cancer (SCLC) treated with chemoradiotherapy, according to a post hoc analysis of the phase III CONVERT trial presented at the European Lung Cancer Conference (ELCC) 2017.
Ensartinib, a small-molecule ALK tyrosine kinase inhibitor (TKI), has demonstrated intracranial response in patients with ALK-positive non-small-cell lung cancer (NSCLC) with central nervous system (CNS) metastases.
Treatment with osimertinib significantly improves symptoms in patients with advanced non-small-cell lung cancer (NSCLC), according to new data from the phase III AURA3 trial presented at the European Lung Cancer Conference (ELCC) 2017.
Patients treated with PD-1/PD-L1 checkpoint inhibitors may be at increased risk of immune-related adverse events (irAEs) after receiving seasonal influenza vaccination, a small study presented at the European Lung Cancer Conference (ELCC) 2017 has shown.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).